Assessment of Quality of Life in Patients with Double-J Ureteral Stents – A Questionnaire-Based Study
DOI:
https://doi.org/10.12775/QS.2026.54.70420Keywords
ureteral stent, double-J stent, quality of life, health-related quality of life (HRQoL), lower urinary tract symptoms (LUTS), stent-related symptoms, urinary urgency, nocturia, urology, urolithiasis, urinary tract obstruction, patient-reported outcomes, questionnaire-based study, stent discomfort, urinary frequency, pain, sexual dysfunctionAbstract
Double-J (DJ) ureteral stents are widely used in modern urology to ensure effective drainage of the upper urinary tract in conditions such as urolithiasis, ureteral obstruction, malignancies, and postoperative management. Despite their clinical benefits, they are often associated with symptoms that impair patients’ quality of life.
The aim of this study was to evaluate the impact of DJ ureteral stents on quality of life in patients treated at the Department of Urology, University Clinical Hospital in Opole, focusing on urinary symptoms, pain, daily functioning, and treatment effectiveness.
The study included 200 patients with indwelling DJ stents. Data were collected using a proprietary questionnaire assessing demographics, indications, stent duration, symptoms, quality of life, and pharmacotherapy. Descriptive statistics were used.
Lower urinary tract symptoms were common, especially nocturia (72%), urgency (68%), and incomplete emptying (61%). Pain was reported by many patients, including lower abdominal (55%) and lumbar pain. Overall, 74% reported reduced quality of life, affecting sleep, work, and sexual activity. Pharmacological treatment was used by 57%, mainly alpha-blockers and anticholinergics; 62% reported improvement, though full relief was rare. Longer stent duration was associated with greater symptom severity.
DJ stents significantly impair quality of life due to frequent symptoms and pain. Pharmacological treatment provides partial relief. Minimizing stent duration and individualized management may reduce morbidity.
References
[1] Joshi HB, Stainthorpe A, MacDonagh RP, et al. Indwelling ureteral stents: evaluation of quality of life. J Endourol. 2001;15(2):151–154.
[2] Damiano R, Oliva A, Esposito C, et al. Early and late complications of double pigtail ureteral stent. Urol Int. 2002;69(2):136–140.
[3] Joshi HB, Newns N, Stainthorpe A, et al. Ureteral stent symptom questionnaire (USSQ). J Urol. 2003;169(3):1060–1064.
[4] Chew BH, Knudsen BE, Denstedt JD. The use of stents in contemporary urology. Curr Opin Urol. 2004;14(2):111–115.
[5] Miyaoka R, Monga M. Ureteral stent discomfort: etiology and management. Indian J Urol. 2009;25(4):455–460.
[6] Dellis A, Joshi HB, Timoney AG, Keeley FX. Relief of stent related symptoms. J Urol. 2010;184(4):1267–1272.
[7] Leibovici D, Cooper A, Lindner A, et al. Ureteral stents: morbidity and impact on QoL. Isr Med Assoc J. 2005;7:491–494.
[8] Irani J, Siquier J, Pirès C, Lefebvre O, Dore B, Aubert J. Symptom characteristics in patients with ureteral stents. J Urol. 1999;162(3):695–698.
[9] Beddingfield R, Pedro RN, Hinck B, et al. Alfuzosin to relieve ureteral stent discomfort. J Urol. 2009;181(1):170–176.
[10] Wang CJ, Huang SW, Chang CH. Effects of tamsulosin on LUTS due to DJ stent. Urol Int. 2009;83(1):66–69.
[11] Yakoubi R, Lemdani M, Monga M, et al. Role of alpha-blockers in stent-related symptoms. J Endourol. 2011;25(3):425–429.
[12] Damiano R, Autorino R, De Sio M, et al. Effect of tamsulosin in stent-related symptoms. Urology. 2008;71(4):695–698.
[13] Lamb AD, Vowler SL, Johnston R, Dunn N, Wiseman OJ. Meta-analysis of alpha-blockers. BJU Int. 2011;108(11):1894–1902.
[14] Nabi G, Cook J, N’Dow J, McClinton S. Stenting after ureteroscopy: meta-analysis. BMJ. 2007;334:572.
[15] Yakoubi R, Lemdani M, et al. Systematic review of stent-related symptoms. J Endourol. 2012;26(7):831–836.
[16] Pengfei S, Yutao L, Jie Y, et al. Role of stenting after ureteroscopy. Urol Res. 2011;39:137–143.
[17] Mosayyebi A, Vijayakumar A, Yue QY, et al. Engineering solutions to ureteral stents. Nat Rev Urol. 2018;15:442–452.
[18] Taguchi K, Yoshida K, Saito H, et al. Impact of ureteral stents on QoL: review. Int J Urol. 2019;26(6):537–543.
[19] Wang HJ, Lee TY, Luo HL, et al. Stent-related symptoms: a comprehensive review. Kaohsiung J Med Sci. 2019;35(8):460–466.
[20] Soria F, Morciano G, et al. Latest developments in ureteral stent technology. Minerva Urol Nefrol. 2020;72(2):135–146.
[21] Betschart P, Zumstein V, Buhmann MT, et al. Symptoms and QoL in ureteral stent patients. World J Urol. 2020;38:2261–2268.
[22] Wang J, Zhao C, Zhang C, et al. Drug therapy for stent-related symptoms: meta-analysis. Front Pharmacol. 2021;12:664923.
[23] Zhang P, Liang Z, Wang X, et al. Pharmacological management of stent discomfort. BMC Urol. 2021;21:25.
[24] Monga M, Klein E, Castaneda-Zuniga WR. Ureteral stents: current status and future directions. J Endourol. 2022;36(3):243–250.
[25] Forbes C, Scotland K, Lange D. Innovations in ureteral stent design. Curr Urol Rep. 2023;24:45–52.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Jakub Hobot
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 7
Number of citations: 0
